Costs and Frequency of Adverse Drug Events in Germany
Author Information
Author(s): Renee G Stark, Jürgen John, Reiner Leidl
Primary Institution: Helmholtz Zentrum München - German Research Center for Environmental Health
Hypothesis
What are the frequency and costs of adverse drug events (ADEs) in outpatient treatment in Germany?
Conclusion
The study found that the costs of adverse drug events in the ambulatory setting in Germany are significant, totaling 816 million Euros.
Supporting Evidence
- The study estimated that about 2 million adults in Germany experienced an ADE in 2007.
- Health care costs related to ADEs totaled 816 million Euros, with significant portions from hospitalizations and long-term care.
- The average cost per ADE case was estimated at 381 Euros.
Takeaway
This study shows that many people in Germany have problems with their medications that can lead to extra costs for healthcare.
Methodology
A cost-of-illness model was adapted to estimate the frequency and costs of ADEs in Germany, using sensitivity analyses based on literature.
Potential Biases
The model may not accurately reflect the true incidence of ADEs due to data scarcity and reliance on U.S. treatment structures.
Limitations
The study relies on limited data from two German hospitals, which may not represent the entire country.
Participant Demographics
The study focused on adults over 20 years of age taking medications in Germany.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website